RUBINSTEIN JULIE sold $897K of ADPT

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.18 ($24.21–$25.82, $0.90M total) across 5 trades over 2026-10-14 to 2026-10-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RUBINSTEIN JULIE
Published Oct 16, 2026, 11:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The disclosed sale may cause short‑term price softness, especially if investors interpret it as a lack of confidence.

02

Market read

Insider sales are closely watched; this filing adds a data point for ADPT's ownership structure.

03

What to watch

The insider retains a sizable stake, and the sale price was near recent trading levels, suggesting no panic.

Relevance 4/10Novelty 5/10Timing: after-hours filing today

Background

Form 4 filings provide the first public disclosure of insider transactions, offering transparency on executive holdings.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

President and COO Julie Rubinstein sold 35,643 shares for $897K via a 10b5‑1 plan, reducing her stake to 377,802 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell

Evidence & confidence

A $0.9M sale by a senior executive is material for a mid‑cap biotech, but the amount is modest relative to market cap, so impact is limited.

Market effects

May prompt scrutiny of insider activity in the biotech sector, but no broader sector shift.

Limited to U.S. biotech investors; no regional effect.

Minimal global impact.

Counterpoint

The sale could be routine under a pre‑arranged plan and not reflect negative outlook.

Key entities

  • Julie Rubinstein

    President and COO of Adaptive Biotechnologies, reporting the sale.

  • Adaptive Biotechnologies Corp

    Biotech firm developing immune profiling technologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.